WO2022218970A3 - Pyrrolobenzodiazepine conjugates - Google Patents
Pyrrolobenzodiazepine conjugates Download PDFInfo
- Publication number
- WO2022218970A3 WO2022218970A3 PCT/EP2022/059730 EP2022059730W WO2022218970A3 WO 2022218970 A3 WO2022218970 A3 WO 2022218970A3 EP 2022059730 W EP2022059730 W EP 2022059730W WO 2022218970 A3 WO2022218970 A3 WO 2022218970A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pyrrolobenzodiazepine conjugates
- pyrrolobenzodiazepine
- conjugates
- formula
- unit
- Prior art date
Links
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical compound C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 title 1
- 239000003446 ligand Substances 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
A conjugate of formula (I): L - (DL)p, wherein L is a Ligand unit (i.e., a targeting agent), p is from 1 to 20, DL is a Drug Linker unit of formula (I'); RLL is a linker for connection to the Ligand Unit, D represents D1; D' represents D'1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB2105187.5 | 2021-04-12 | ||
GBGB2105187.5A GB202105187D0 (en) | 2021-04-12 | 2021-04-12 | Pyrrolobenzodiazepine conjugates |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2022218970A2 WO2022218970A2 (en) | 2022-10-20 |
WO2022218970A3 true WO2022218970A3 (en) | 2022-12-29 |
Family
ID=75949628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2022/059730 WO2022218970A2 (en) | 2021-04-12 | 2022-04-12 | Pyrrolobenzodiazepine conjugates |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB202105187D0 (en) |
WO (1) | WO2022218970A2 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013177481A1 (en) * | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
WO2014057074A1 (en) * | 2012-10-12 | 2014-04-17 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
WO2020079229A1 (en) * | 2018-10-19 | 2020-04-23 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
WO2020205564A1 (en) * | 2019-03-29 | 2020-10-08 | Immunogen, Inc. | Cytotoxic bis-benzodiazepine derivatives and conjugates thereof with cell-binding agents for inhibiting abnormal cell growth or for treating proliferative diseases |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58180487A (en) | 1982-04-16 | 1983-10-21 | Kyowa Hakko Kogyo Co Ltd | Antibiotic dc-81 and its preparation |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
PL1720881T3 (en) | 2004-03-01 | 2013-05-31 | Medimmune Ltd | 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepins |
SI1791565T1 (en) | 2004-09-23 | 2016-08-31 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
PT1879901E (en) | 2005-04-21 | 2010-03-29 | Spirogen Ltd | Pyrrolobenzodiazepines |
PL1813614T3 (en) | 2006-01-25 | 2012-03-30 | Sanofi Sa | Cytotoxic agents comprising new tomaymycin derivatives |
CA2683568A1 (en) | 2007-05-08 | 2008-11-20 | Genentech, Inc. | Cysteine engineered anti-muc16 antibodies and antibody drug conjugates |
US8937161B2 (en) | 2007-10-19 | 2015-01-20 | Genentech, Inc. | Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates |
JP5972864B2 (en) | 2010-04-15 | 2016-08-17 | メディミューン リミテッド | Pyrrolobenzodiazepines and their conjugates |
FR2967466B1 (en) | 2010-11-16 | 2014-10-24 | Renault Sa | METHOD FOR DETECTING COMBUSTION FAULTS OF AN INTERNAL COMBUSTION ENGINE |
GB201106173D0 (en) | 2011-04-12 | 2011-05-25 | Adc Biotechnology Ltd | System for purifyng, producing and storing biomolecules |
EP2935268B2 (en) | 2012-12-21 | 2021-02-17 | MedImmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
RU2711485C2 (en) | 2014-04-11 | 2020-01-17 | МЕДИММЬЮН, ЭлЭлСи | Conjugated compounds containing cysteine-constructed antibodies |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
KR20190083654A (en) | 2016-11-10 | 2019-07-12 | 메디뮨 엘엘씨 | Binding molecules specific for ASCT2 and uses thereof |
CN112203696A (en) | 2018-05-25 | 2021-01-08 | 免疫医疗有限公司 | Pyrrolobenzodiazepine conjugates |
-
2021
- 2021-04-12 GB GBGB2105187.5A patent/GB202105187D0/en not_active Ceased
-
2022
- 2022-04-12 WO PCT/EP2022/059730 patent/WO2022218970A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013177481A1 (en) * | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
WO2014057074A1 (en) * | 2012-10-12 | 2014-04-17 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
WO2020079229A1 (en) * | 2018-10-19 | 2020-04-23 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
WO2020205564A1 (en) * | 2019-03-29 | 2020-10-08 | Immunogen, Inc. | Cytotoxic bis-benzodiazepine derivatives and conjugates thereof with cell-binding agents for inhibiting abnormal cell growth or for treating proliferative diseases |
Non-Patent Citations (4)
Title |
---|
BREANNA S. VOLLMAR ET AL: "Synthesis and evaluation of pyrrolobenzodiazepine dimer antibody-drug conjugates with dual [beta]-glucuronide and dipeptide triggers", BIOCONJUGATE CHEMISTRY, vol. 28, no. 10, 22 September 2017 (2017-09-22), pages 2538 - 2548, XP055551756, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.7b00365 * |
GREGSON STEPHEN J ET AL: "Synthesis and evaluation of pyrrolobenzodiazepine dimer antibody-drug conjugates with dual [beta]-glucuronide and dipeptide triggers", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 179, 18 June 2019 (2019-06-18), pages 591 - 607, XP085772542, ISSN: 0223-5234, [retrieved on 20190618], DOI: 10.1016/J.EJMECH.2019.06.044 * |
KATIE E. ARCHER ET AL: "Synthesis of Highly Potent N-10 Amino-Linked DNA-Alkylating Indolinobenzodiazepine Antibody-Drug Conjugates (ADCs)", ACS MEDICINAL CHEMISTRY LETTERS, vol. 10, no. 8, 22 July 2019 (2019-07-22), pages 1211 - 1215, XP055705444, ISSN: 1948-5875, DOI: 10.1021/acsmedchemlett.9b00254 * |
NAZZARENO DIMASI ET AL: "Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Cysteine Insertion", MOLECULAR PHARMACEUTICS, vol. 14, no. 5, 16 March 2017 (2017-03-16), pages 1501 - 1516, XP055417109, ISSN: 1543-8384, DOI: 10.1021/acs.molpharmaceut.6b00995 * |
Also Published As
Publication number | Publication date |
---|---|
WO2022218970A2 (en) | 2022-10-20 |
GB202105187D0 (en) | 2021-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006060533A3 (en) | Conjugates of 1, 8-bis-naphthalimides with an antibody | |
WO2007064345A3 (en) | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use | |
MY197127A (en) | Pyrrolobenzodiazepine conjugates | |
AU3000800A (en) | Phosphocholine linked prodrug derivatives | |
MX2013014583A (en) | Protein-polymer-drug conjugates. | |
NZ588851A (en) | Potent conjugates and hydrophilic linkers | |
TW200500069A (en) | Vitamin-receptor binding drug delivery conjugates | |
JO2744B1 (en) | Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use | |
NZ597964A (en) | Long acting insulin composition | |
MX2018009585A (en) | Pyrrolobenzodiazepine conjugates. | |
MA28653B1 (en) | NEW FLUOROGLYCOSIDE DERIVATIVES OF PYRAZOLES, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND THEIR USE | |
TW200637869A (en) | The spiroketal derivatives and the use as therapeutical agent for diabetes of the same | |
GB0220198D0 (en) | Modified saccharides,conjugates thereof and their manufacture | |
MA34469B1 (en) | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | |
WO2008076333A3 (en) | Polymer-drug conjugates with tether groups for controlled drug delivery | |
WO2011010084A8 (en) | Cyclosporin conjugates | |
Ghosh et al. | Chemical and biological explorations of the family of CC-1065 and the duocarmycin natural products | |
AU2003250391A1 (en) | Conjugates of biocompatible polymers with nuclide activation therapy reagents | |
MX2022008997A (en) | Compounds and conjugates thereof. | |
AU2002215904A1 (en) | Compounds with a branched linker | |
MX2023001648A (en) | Antibody drug conjugate. | |
JOP20210083A1 (en) | Antibody drug conjugates comprising ecteinascidin derivatives | |
BR0112807A (en) | Indole derivatives and their application as a medicine | |
WO2006105201A3 (en) | Conjugates comprised of fatty acid and hiv gp41-derived peptide | |
WO2022218970A3 (en) | Pyrrolobenzodiazepine conjugates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22722261 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22722261 Country of ref document: EP Kind code of ref document: A2 |